Pregabalin Capsule
Product Images NDC 72162-1543

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621543)

Each capsule of Pregabalin USP 75 contains 75mg of pregabalin. This drug should be kept out of reach of children and stored at room temperature (20°-25°C or 68°-77°F). These capsules are manufactured by ScieGen Pharmaceuticals, Inc. and repackaged by Bryant Ranch Prepack, Inc. This drug is available only by prescription.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

The text seems to contain some numeric values related to patient improvement and pain reduction. However, the characters are not organized and some of them couldn't be identified by the . Therefore, it's not possible to generate a useful description.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

This appears to be a chart showing the percentage of patients who experienced improvement in pain levels after taking a medication called Pregabalin at a dose of 160 mg for a period of 3 days. The chart shows different pain scores at different time intervals (2w, 220, 23, 20, 280, 2, 20, 2w, 23w) and the corresponding percentage of patients who experienced improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

This text appears to be a mix of numerical data and medication names and dosages. It is not clear what the context or purpose of the data is. Thus, the description cannot be provided.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

The text appears to show the names and doses of medications being administered to patients, as well as some data related to their improvement in pain. However, the text contains many errors and is not readable.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

This appears to be a table or graph showing data from multiple studies with different treatment groups and dosages. The names of the studies are E1 and E3, and there is a treatment group labeled S5. The data includes dosage amounts (ranging from placebo to 600mg/day) and a note that the results were statistically significant compared to the placebo group. Therefore, this text appears to be a partial report of clinical trial results for a treatment being studied.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

The text provides a chart that compares the percent of patients improved with a daily dose of Pregabalin 300mg and Pregabalin 450mg. There is another column for the placebo group. The chart also shows the percent of improvement in pain from baseline. No additional information is available.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This appears to be a chart or table showing estimated percentages of subjects without LTR (potentially related to a medical trial or study) over a certain number of days. The chart includes two groups: one labeled "Progabain" and the other labeled "Placebo". Unfortunately, as can sometimes produce errors when converting text, the exact meaning or context of the chart cannot be confirmed without further information.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

The text is describing a table or graph showing the percentage of subjects who improved after taking either Pregabalin or a placebo for 16 weeks. The chart displays a range of numbers from 100 to 280 and shows that there was a percentage increase in improvement for those taking Pregabalin. However, without additional context or units of measurement, it's challenging to draw further conclusions from the provided text.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This appears to be a calculation for estimating creatinine clearance using the Cockcroft-Gault formula, which takes into account a person's age, weight, and serum creatinine level. The mm's represent an unknown value that would need to be replaced with a number, and the "e e" likely represents "x 0.85" for female patients. However, without knowing the actual values for age, weight, and serum creatinine, it's not possible to determine an accurate estimate of creatinine clearance.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.